Navigation Links
Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells
Date:7/24/2014

CAMBRIDGE, Mass. (July 24, 2014) For years, researchers and patients have hoped that embryonic stem cells (ESCs)capable of forming nearly any cell type in the bodycould provide insight into numerous diseases perhaps even be used to treat them. Yet progress has been hampered by the inability to transfer research and tools from mouse ESC studies to their human counterparts, in part because human ESCs are "primed" and slightly less plastic than the mouse cells.

Now Thorold Theunissen, Benjamin Powell, and Haoyi Wang, who are scientists in the lab of Whitehead Institute Founding Member Rudolf Jaenisch, have discovered how to manipulate and maintain human ESCs in a "nave" or base pluripotent state similar to that of mouse ESCs without the use of any reprogramming factors. Their work is described in this week's issue of the journal Cell Stem Cell.

Nave mouse ESCs are well-studied, and scientists have a strong understanding of how they function and mature into more specialized cells. But this understanding is of limited use in human ESC research, as the human cells look different, grow differently, and rely on different genes than mouse ESCs. According to Theunissen, the disparities between mouse and human ESCs are attributable not to species-specific differences but rather to differences of cell state.

In nave mouse ESCs, a particular enhancer of the gene OCT4 is active, prompting the researchers to look for the presence of this marker as a means to identify rare nave human ESCs. With this unbiased reporter system in hand, the Jaenisch team determined that a cocktail of five small molecules with a few additional growth factors can induce and support the conversion of primed human ESCs to a nave state with or without using reprogramming factors to jumpstart the process.

By applying this cocktail to human blastocysts, the scientists could also isolate nave human stem cells.

"This is important because if this cocktail only works in existing lines of human ESCs, you might wonder, does this really capture a distinct state or is this artificial?" says Theunissen. "Since the cocktail works directly on human blastocysts, I think it suggests that we're really capturing a cell state that is already present in the early human embryo."

Although other labs have recently reported creating nave human ESCs, Theunissen, Powell, and Wang question these results as the cells produced through these techniques lack the gene expression and epigenetic profiles of nave human ESCs. Yet, the Jaenisch lab believes they have now finally unlocked a way to create and maintain this important type of cell and are looking forward to exploring its potential.

"We have discovered a new pathway to generate something we believe is a totally different state of pluripotency in human ESCs that is very close to the mouse nave state," says Jaenisch, who is also a professor of biology at MIT. "These cells may be essential for ESC technology, and that is an area we're looking forward to investigating. Now the big question for us is, does this state exist in vivo in embryos? Right now, we don't know, and that is a very interesting line of research."


'/>"/>

Contact: Nicole Giese Rura
rura@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research
Source:Eurekalert

Related biology news :

1. Whitehead scientists identify major flaw in standard approach to global gene expression analysis
2. Diabetes Research Institute develops oxygen-generating biomaterial
3. Space research institute honors Sen. Hutchison with Pioneer Award
4. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
5. Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network
6. Cary Institute Hydrofracking Forum
7. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
8. Scripps Research Institute scientists develop antidote for cocaine overdose
9. NJIT, Chinas Bengbu Glass Institute sign agreement for R&D, training
10. Merkin Family Foundation to fund next generation of Broad Institute scientists
11. TGen leads new National Institutes of Health study of brain tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... -- Aware, Inc. (NASDAQ: AWRE), a leading supplier of biometrics ... has resigned, effective March 3, 2017, as co-Chief ... Treasurer of Aware citing a desire to retire.  Mr. ... the Board of Directors of Aware. ... co-President, General Counsel has been named Chief Executive Officer, ...
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider ... that its board of directors has amended its shareholder rights plan. The ... 2017 to March 27, 2018. The amendment was not in response to ... ... Ltd. is a China -based biopharmaceutical company that ...
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... 2017  SeraCare Life Sciences, Inc., a manufacturer ... diagnostics manufacturers and clinical laboratories, is announcing ... Inherited Cancer reference material for ... sequencing (NGS). The Seraseq™ Inherited Cancer DNA Mix ... industry experts to validate the ability of ...
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
Breaking Biology Technology: